|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39.50 USD | +2.60% |
|
+5.31% | +18.76% |
| Dec. 29 | Azenta to Sell B Medical Systems Business | MT |
| Dec. 19 | Needham Raises Price Target on Azenta to $44 From $42, Keeps Buy Rating | MT |
| Capitalization | 1.82B 1.56B 1.45B 1.35B 2.52B 164B 2.72B 16.69B 6.56B 78.45B 6.81B 6.67B 287B | P/E ratio 2026 * |
125x | P/E ratio 2027 * | 69.3x |
|---|---|---|---|---|---|
| Enterprise value | 1.82B 1.56B 1.45B 1.35B 2.52B 164B 2.72B 16.69B 6.56B 78.45B 6.81B 6.67B 287B | EV / Sales 2026 * |
2.94x | EV / Sales 2027 * | 2.78x |
| Free-Float |
74.95% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Azenta, Inc.
| 1 day | +2.60% | ||
| 1 week | +5.31% | ||
| Current month | +18.76% | ||
| 1 month | +11.90% | ||
| 3 months | +29.08% | ||
| 6 months | +22.56% | ||
| Current year | +18.76% |
| 1 week | 37.05 |  | 39.67 |
| 1 month | 32.94 | | 39.67 |
| Current year | 32.94 | | 39.67 |
| 1 year | 23.91 | | 55.64 |
| 3 years | 23.91 | | 69.16 |
| 5 years | 23.91 | | 124.79 |
| 10 years | 8.33 | | 124.79 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Marotta
CEO | Chief Executive Officer | 45 | 2024-09-08 |
Lawrence Lin
DFI | Director of Finance/CFO | 49 | 2024-11-30 |
Rob Woodward
CTO | Chief Tech/Sci/R&D Officer | - | 2009-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Robyn Davis
BRD | Director/Board Member | 65 | 2013-06-27 |
Erica McLaughlin
BRD | Director/Board Member | 50 | 2020-04-02 |
Frank Casal
CHM | Chairman | 72 | 2024-01-29 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +6.06% | 1.74% | 148 M€ | |
| 0.00% | 0.21% | 22 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.60% | +5.31% | -23.21% | -33.97% | 1.82B | |
| +0.90% | +1.63% | +3.09% | +11.71% | 49.05B | |
| -0.09% | -1.20% | +21.92% | +8.65% | 41.1B | |
| -1.23% | +3.86% | +72.52% | +28.11% | 38.37B | |
| -4.30% | +0.24% | +19.22% | +36.66% | 31.59B | |
| +1.06% | +18.02% | +204.34% | +302.86% | 23.43B | |
| +1.32% | +0.55% | +86.29% | +169.71% | 17.36B | |
| +8.08% | -33.49% | +27,398.05% | +4,371.14% | 17.39B | |
| +0.25% | +4.76% | +55.68% | +11.16% | 14.83B | |
| +0.81% | -8.94% | -7.73% | -17.69% | 14.11B | |
| Average | +0.92% | -1.07% | +2,783.02% | +488.83% | 24.91B | |
| Weighted average by Cap. | +0.24% | -0.20% | +1,958.94% | +357.69% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 618M 531M 494M 460M 858M 55.83B 925M 5.68B 2.23B 26.71B 2.32B 2.27B 97.85B | 654M 561M 523M 486M 908M 59.06B 979M 6.01B 2.36B 28.25B 2.45B 2.4B 104B |
| Net income | 14.28M 12.25M 11.41M 10.62M 19.81M 1.29B 21.36M 131M 51.6M 617M 53.55M 52.44M 2.26B | 26M 22.31M 20.77M 19.33M 36.07M 2.35B 38.88M 239M 93.94M 1.12B 97.5M 95.49M 4.11B |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-14 | 39.50 $ | +2.60% | 670,626 |
| 26-01-13 | 38.50 $ | +2.56% | 500,829 |
| 26-01-12 | 37.54 $ | -1.00% | 425,469 |
| 26-01-09 | 37.92 $ | +1.12% | 475,944 |
| 26-01-08 | 37.50 $ | -0.03% | 380,121 |
Delayed Quote Nasdaq, January 14, 2026 at 04:00 pm EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZTA Stock
Select your edition
All financial news and data tailored to specific country editions
